+34 679 490 537info@nanbiosis.com

JUMISC

JUMISC

Why peripheral blood lymphocyte alterations can be good biomarkers to predict myocardial infarction severity

Researchers of CCMIJU led by Verónica Crisóstomo, Scientific Director of NANBIOSIS U24 Medical imaging, and Javier García Casado Scientific Director of NANBIOSIS U14 Cell Therapy unit have carried out a study study aimed to identify which are the very early immune-related biomarkers that may be used as predictors of myocardial infarction severity.

Experimental studies have been conducted by NANBIOSIS Units 14, 21, 22 and 24 of the CCMIJU, clinical test lab, animal housing, experimental operating room and medical imaging tecniciansare are recognized in the acknowledgement and funding sections of the article.

Article of reference:

Esther López, Francisco Miguel Sánchez-Margallo, Verónica Álvarez, Rebeca Blázquez, Federica Marinaro, Ana Abad, Helena Martín, Claudia Báez,Virginia Blanco,Verónica Crisóstomo and Javier García Casado “Identification of very early inflammatory markers in a porcine myocardial infarction model” BMC Veterinary Research 2019-15:91

Read More

The European Union highlights the relevance of the JUMISC’s Cutting-Edge Infraestructures and Technology, recognized as ICTS.

Jesús Usón Minimally Invasive Surgery Center (JUMISC), from Cáceres, partnert of NANBIOSIS, has recently made headlines on the website of the European Commission as an innovative center for Biomedical and Health Research.

In the interview to his Director, Francisco Miguel Sanchez Margallo, he explained how European Funds allowed Infraestructures and Vanguard Technology for biomedical research at the CCMIJU, which have already been recognized, as part of NANBIOSIS, with CIBER-BBN and BIONAND, as “Singular Scientific and Technical Infrastructure” (ICTS).

Complete news at European Commision’s Website: https://ec.europa.eu/spain/news/investeu_caceres_es

https://ec.europa.eu/spain/news/investeu_caceres_es
Read More

GLP Analytical Validation Study in Different Animal Species

Beatriz Moreno Lobato and Francisco Miguel Sánchez Margallo, Scientific Director and Coordinator of NANBIOSIS unit 19 Clinical tests lab at CCMIJU, have reclently published an study in the journal Thrombosis & Haemostasis: Research, with the aim to contribute with methodological results data to help the researcher to establish the validation of the analytical methods used within the research.

Good Laboratory Practice (GLP) is a quality system of management controls to ensure the uniformity, consistency, reliability, reproducibility, quality, and integrity of pre-clinical safety tests.

In the study, different hematological parameters (WBC, RBC, HB, HCT, MCV, MCH, MCHC, and PLT) were validated in pig, sheep, dog and rabbit, calculatting the repeatability and the intermediate precision . The obtained results were statistically analyzed; the mean, the standard deviation and the coefficient of variation were calculated.

The study results ensure the quality and integrity of the measurements obtained in the CCMIJU Clinical tests lab (unit 19 of NANBIOSIS), which is necessary in the performance of preclinical studies.

Article of reference: Moreno-Lobato B and Sánchez-Margallo FM. Analytical Validation Study of Hematological Parameters under Good Laboratory Practice Regulations in Different Laboratory Animal Species. Thromb Haemost Res. 2019; 3(1): 1018.

Read More

NANBIOSIS Scientific Women in the International Day of Women and Girls in Science

Today February 11 is the International Day of Women and Girls in Science, a day to raise awareness of the gender gap in science and technology.

According to the United Nations, while yet women and girls continue to be excluded from participating fully in science, science and gender equality are vital to achieve the internationally agreed development goals, including the 2030 Agenda for Sustainable Development. Thus, in recent years, the international community has made a great effort to inspire and promote the participation of women and girls in science.

NANBIOSIS wants to acknowledge  the efforts made by scientific women who struggle every day to contribute their bit to Science and highlight their essential role in nowadays research. Especially we want to recognize the work of scientists women involved in our units, whatever is the nature of their contribution: technical, scientific development, management, coordination, direction, etc; just to mention some examples:
Neus Ferrer in the Scientific Direction of Unit 1 Protein Production Platform (PPP)
Pilar Marco and Nuria Pascual in the Management and Scientific Coordination of U2 Custom Antibody Service (CAbS) 
Miriam Royo in the Scientific Direction of U3 Synthesis of Peptides Unit
Laura Lechuga and M.Carmen Estevez in the Direction and Scientific Coordination of U4 Biodeposition and Biodetection Unit
Nora Ventosa and Nathaly Segovia in the Scientific Direction and Technical Coordination of U6 Biomaterial Processing and Nanostructuring Unit
Isabel Oliveira and Teresa Galán in the Coordination of U7 Nanotecnology Unit
Rosa Villa and Gemma Gabriel in the Management and Scientific Coordination of U8 Micro – Nano Technology Unit
Gema Martínez in the Scientific Coordination of U9 Synthesis of Nanoparticles Unit
Fany Peña in the Scientific Coordination of U13 Tissue & Scaffold Characterization Unit
Mª Luisa González Martín in the of Direction and Scientific Coordination of U16 Tissue & Scaffold Characterization Unit
Gemma Pascual and Isabel Trabado in the Coordination of the U17 Confocal Microscopy Service
Mª Virtudes Céspedes in the Scientific Coordination of U18 Nanotoxicology Unit
Beatriz Moreno in the Scientific Direction of Unit 19 Clinical tests lab
Ibane Abásolo in the Scientific Coordination of Unit 20 In Vivo Experimental Platformt
Verónica Crisóstomo in the Scientific Direction of Unit 24 Medical Imaging 

Ana Paula Candiota in the Scientific Coordination of Unit 25 Biomedical Applications I 
Maria Luisa García in the Scientific Direction of U28 NanoImaging Unit from Bionand, recently incorporated to NANBIOSIS

Read More

PICCOLO PROJECT FACE-TO-FACE MEETING

The 5th project face to face meeting has taken place in Cáceres (Spain). The first version of the PICCOLO prototype was set up at CCMIJU, facilities at the end of 2018, and it has been a great chance to show it to the PICCOLO consortium members. During these two days of the meeting, the technical partners presented both the individual components of the prototype (MPT and OCT) and the integration of the same in the probe of the multi-photonic system. The attendants have been able to check in-situ the performance of the prototype in the operating rooms of CCMIJU. Based on this, and in close collaboration with clinical partners, next steps regarding the pre-clinical tests on animal models to be performed were discussed.

This project has received funding from the European Union’s Horizon 2020 research and innovation Programmeunder Grant Agreement No. 732111

Image of the meeting participants at the face to face meeting in the JUMISC, partner of NANBIOSIS.

Read More

STRYKER & NANBIOSIS start a promising line of biomedical research collaboration

On January 23-24th a two-day meeting between NANBIOSIS and Stryker Trauma GmbH, took place at the Carlos III Health Institute, in Madrid, to explore synergies and potential joint initiatives.  

Nils Reimers and Robin Buescher from Stryker, presented some of their research and upcoming projects in the field of trauma medical devices, and representatives from NANBIOSIS’ units -Marisa González from U16 Surface Characterization and Calorimetry Unit, Teresa Galán from U7, Nanotechnology Unit, Gemma Pascual from U17 Confocal Microscopy Service, from CIBER-BBN, Marisa García from U28 (Bionand) and José Francisco Guillén and Francisco Sanchez Margallo from the units of the Jesús Usón Minimum Invasive Surgery Center (CCMIJU) , together with Jesús, Izco Executive Director of NANBIOSIS and Ramon Martínez, Scientific Director of CIBER-BBN- explained their technologies.

The second day, the meeting location was moved to the CCMIJU in Cáceres, to visit the Center facilities and continue conversations.

All attendees expressed their satisfaction with the development of the meeting and agreed to continue with the explorations in forthcoming meetings.

Photo caption: From left to right: José Francisco Guillén (Quality Guarantee Manager of CCMIJU),  Jesús Izco (NANBIOSIS Executive Director), Francisco Sanchez Margallo (Scientific Director of CCMIJU), Nils Reimers (Senior Manager R&D – Stryker Trauma GmbH), Robin Buescher (Director R&D Stryker Trauma GmbH), Margarita Casado (Management Staff of NANBIOSIS)”

Read More

NANBIOSIS resarchers in CCMIJU identify biomarkers for bridging the gap between preclinical studies in large animal models and clinical trials

Researchers of NANBIOSIS Units at CCMIJU have publish a very relevant article about the studies on  hematological, biochemical and immunological parameters, as well as magnetic resonance derived cardiac function measurements obtained from a swine myocardial infarction model that allows to predict the severity of myocardial infarction in a clinically relevant animal model providing a  simple, affordable and reliable way that could prove useful in the follow up of myocardial infarction and in the evaluation of new therapeutic strategies in this animal model.

Biochemical and hematological determinations were performed by the ICTS Nanbiosis (Unit 19. Clinical test lab at CCMIJU). Flow cytometry analyses were performed by the ICTS Nanbiosis (Unit 14. Cell therapy at CCMIJU). Blood sampling and maintenance of animals were performed by the ICTS Nanbiosis (Unit 22. Animal housing at CCMIJU). Myocardial infarction induction and Magnetic Resonance studies waere performed by the ICTS Nanbiosis (Unit 21. Experimental operating rooms and Unit 24. Medical imaging at CCMIJU).

Article of reference: “Altered hematological, biochemical and immunological parameters as predictive biomarkers of severity in experimental myocardial infarction” DOI: https://doi.org/10.1016/j.vetimm.2018.10.007

 

Read More

JUMISC OBTAINS TWO INTERNATIONAL RECOGNITIONS AT THE ANNUAL MEETING OF THE LAPAROSCOPIC SURGEONS SOCIETY HELD IN NEW YORK

Dr. Francisco Miguel Sánchez Margallo,  Assistant Director of NANBIOSIS and Scientific Director of JUMISC, has attended the multidisciplinary Congress organized by the Society of Laparoendoscopic Surgeons (SLS), held in New York from August 29 to September 1, where he has presented scientific communications with very innovative results in the specialty of urology.

At the annual meeting of this Scientific Society, international specialists related to minimally invasive surgery meet, with the aim of increasing knowledge of laparoscopic, endoscopic and minimally invasive surgical techniques, including robotic surgery.

The papers presented by Dr. Francisco M. Sánchez Margallo, have received the Harrith M. Hasson Award for the best oral communication, for promoting Teaching and Training in the specialty of urology. He has received this award from the wife of Dr. Hasson, one of the pioneers in laparoscopic surgery and inventor of the open laparoscopic technique and the trocar that bears his name.

The objectives of this work are focused on developing a platform for training and surgical assistance in urology, based on mixed reality technology. In addition, an application with this technology is incorporated for viewing, in real time, by surgeons of tomography, resonance and three-dimensional models of patients.

The results of this work have been tested by different experts of the Spanish Association of Urology (AEU) in the operating rooms of the Center, through an application that allows viewing, in real time, the preoperative studies of tomography, resonance and a human pelvic model. in 3D, through a recreation in the Hololens mixed reality glasses, marketed by the Microsoft company.

The second of the papers presented by Dr. Sánchez Margallo has received a mention of scientific honor, showing the results of the analysis of surgical skills and ergonomic studies of surgeons during the use of a novel robotic device in laparoscopic urological surgery.

These studies have involved different professionals from the clinical and technological areas of the Center and collaborators of the Biomechanics group of the University of Extremadura (UEX) and the CIBEX technology company, in addition to the advice of various Spanish urologists.

The Jesús Usón Minimally Invasive Surgery Center Foundation is a unique infrastructure that works in research, training and innovation in the health field.

Read More

COURSE FOR THE PERFORMANCE OF FUNCTIONS A, B AND C IN RODENTS, LAGOMORFOS, CARNIVORES, PIGS AND SMALL RUMINANTS

On November 2th-30th, Centro de Cirugía de Mínima Invasión Jesús Usón, partner of NANBIOSIS, organizes a theorical and practical course:  “Course for the performance of functions a, b and c in rodents, lagomorfos, carnivores, pigs and small ruminants”. Some researchers of NANBIOSIS Units at JUMISC, will transmit their knowhow and experience to the attendees.

The course objetives are to provide adequate training to researchers in the science and welfare of the laboratory animal, as well as the use of bloodless methods of euthanasia that will be carried out with experimental animals in accordance with current legislation and existing recommendations.

This course, once met all the requirements demanded by the Competent Authority (supervised work period) by the students, will provide accreditation for the performance of FUNCTIONS A (care of animals), B (euthanasia of animals) and C (realization of procedures), granted by the Ministry of Environment and Rural, Agrarian Policies and Territory. These functions correspond to those established in article 15, point 2 letters a), b) and c) of Royal Decree 53/2013, of February 1, which establishes the basic rules applicable for the protection of animals used in experimentation and other scientific purposes, including teaching

Program

Inscription

 

Read More

Use of Nanomedicine in preclinical studies and animal models

In this video, Beatriz Moreno Lobato, Head of Unit 19 of NANBIOSIS, Clinical Tests Lab and head of the Animal Modeling Service and Clinical Analysis Laboratory of CCMIJU, gives a talk about the use of Nanomedicine in preclinical studies and animal models. Models of type I and II diabetes, cutaneous ulcer models, animal models in ophthalmology, urology models, cartilage defect models or bone defects models and cardiovascular models such as mycardial infarction in pig that Beatriz explains in more detail, as well as implantation of surgical material in combination with adult stem cells

Read More